Takeaways: The main market signal is strategic rather than commercial: Health Canada’s clearance, alongside PHAC’s collaboration with Moderna, helps de-risk the company’s mRNA infectious-disease...
GSK’s Shingrix prefilled syringe presentation approved in Canada GSK Canada announced that Health Canada has approved a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine) fo...
CDA-AMC recommends public reimbursement of LEQEMBI (lecanemab) for early Alzheimer’s disease Eisai Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive recommendation...
Canada’s biotechnology industry is entering a defining era of scientific innovation, global investment, and clinical excellence. The Leading 10 Canadian Biotech Companies of 2026 report highligh...
Artificial intelligence is rapidly becoming embedded across the pharmaceutical value chain, from drug discovery and clinical trial optimization to manufacturing and commercialization. As the technolog...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
Patient centricity has become one of the most widely used, and often overused, terms in the biopharma industry. In Canadian Health discussions, nearly every stakeholder references it in some form, emb...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
For all the scientific advances in drug development, clinical trials remain one of the most inefficient and fragile components of the system. Patient recruitment is slow and costly, retention rates ar...
Artificial intelligence has rapidly moved from a buzzword to a core component of modern drug development. From target identification and molecule design to clinical trial optimization, AI pr...
